VentriPoint Diagnostics Ltd.
TSX VENTURE : VPT
OTCQX : VPTDF

VentriPoint Diagnostics Ltd.

June 06, 2012 10:00 ET

Six Medical Centres Operational and University of Chicago Commences Enrollment in VentriPoint Clinical Trial in Pulmonary Arterial Hypertension

Multiple Centres Now Actively Enrolling Patients

SEATTLE, WASHINGTON--(Marketwire - June 6, 2012) - VentriPoint Diagnostics (TSX VENTURE:VPT) (OTCQX:VPTDF) announces it has installed the VMS™ heart analysis system in six leading medical centres in the United States and Canada to enable the multi-centre clinical trial to assess the VentriPoint Medical System (VMS™) in patients with Pulmonary Arterial Hypertension (PAH). In addition, the University of Chicago has joined Allegheny General Hospital in Pittsburgh (see press release May 11, 2012) in enrolling patients and has already completed its first three patients.

"We are excited to be part of the PAH multi-centre clinical trial," stated Dr. Mardi Gomberg-Maitland, Associate Professor of Medicine, Director of the Pulmonary Hypertension Center, University of Chicago Medical Center.

Dr. George Adams, VentriPoint President and CEO stated, "The Company is pleased the expert group at the University of Chicago will be part of the multi-centre clinical trial and have already enrolled three patients in the study."

The clinical trial will study 75 patients with PAH using both cardiac MRI and the VMS™ ultrasound approaches on the same day. It is anticipated enrollment will be competed this summer and a submission sent to the FDA in 3Q12.

The VMS™ is for investigational use only in the United States and approved for clinical use in Canada and Europe.

About VentriPoint Diagnostics Ltd.

VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease in children is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure - a multi-billion dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of its VMS™ diagnostic tool and is pursuing the US-FDA approval through the 510(k) process.

FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Contact Information